Clinical Trials
3 trialsNCT04074759 2025-01-23
FPT155-001
Five Prime Therapeutics, Inc.
Phase 1 Terminated
NCT05394350 2024-11-08
MK-1088-002
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT02880371 2022-06-16
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Pfizer
Phase 1/2 Terminated